ClinicalTrials.gg
CompletedNCT03754790ATLAS-OLEUpdated Sep 30, 2026

Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX

A Phase 3 interventional study of Fitusiran in Hemophilia, sponsored by Genzyme, a Sanofi Company. Completed at 79 sites in 20 countries. Open to male participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Genzyme, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Treatment

Updated Sep 30, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
281
Allocation
Not applicable
Ages
12 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing fitusiran in Hemophilia A — 2 open to participants now, 3 under way, 2 of them phase 3. fitusiran · Hemophilia A.

Enrollment
Largest of 10
281 · median 70
Started
2019
the only one that year
Phase 3
6 of 10
1 open now
Registered
6th of 10
by date
Lead sponsor
6 of 10
Genzyme, a Sanofi Company

Among the 10 studies testing fitusiran in Hemophilia A, this one has the largest enrollment, is the only one that started in 2019, is one of 6 in phase 3, and was the 6th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

2 of the 10 studies testing fitusiran in Hemophilia A are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About fitusiran

fitusiran: first FDA approval 2025 (QFITLIA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 12 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing fitusiran in Hemophilia A, or all of them as a file.
02

Study summary

Primary Objective:

To characterize the long-term safety and tolerability of fitusiran

Secondary Objectives:

  • To characterize the efficacy and long-term efficacy of fitusiran as assessed by the frequency of:

    • Bleeding episodes
    • Spontaneous bleeding episodes
    • Joint bleeding episodes
  • To characterize the effects of fitusiran on health-related quality of life (HRQOL) measures in participants ≥17 years of age
Read the detailed description

The estimated total time on the study for a participant is up to 90 months (including screening, treatment period and safety follow up period).

03

Conditions studied

  • Hemophilia

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be at least 12 years of age inclusive, at the time of signing the
  • Participants with severe hemophilia A or B who have completed a Phase 3 fitusiran clinical trial
  • Male
  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol. In countries where legal age of majority is above 18 years, a specific ICF must also be signed by the participant's legally authorized representative

Exclusion criteria

Exclusion criteria:

  • Completion of a surgical procedure within 14 days prior to screening, or currently receiving additional factor concentrate or BPA infusion for postoperative hemostasis
  • Current participation in immune tolerance induction treatment (ITI)
  • Current use of factor concentrates or bypassing agents (BPAs) as regularly administered prophylaxis designed to prevent spontaneous bleeding episodes except for participants requiring factor concentrates or BPAs prophylaxis during the study dosing pause period
  • Use of compounds other than factor concentrates or BPAs for hemophilia treatment
  • Current or prior participation in a gene therapy trial
  • (ALT) and/or Aspartate aminotransferase (AST) >1.5 × reference range (ULN) for patients who are naïve to fitusiran at study start; ALT and/or AST > 5 x ULN for patients who were in the fitusiran arm in the parent study
  • Additional exclusions for participants not currently participating in a fitusiran trial at the time of enrollment in the lower dose cohort:

    • liver disease
    • History of arterial or venous thromboembolism

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
281 participants (actual)

Study arms

  • Experimental
    Fitusiran

    Participants will be administered fitusiran as a subcutaneous injection once monthly or every other month for up to 48 months post initiation of modified IMP dose/frequency or until fitusiran becomes commercially available, whichever comes first.

    Drug: Fitusiran

Interventions

  • Pharmaceutical form:solution for injection Route of administration: subcutaneous

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment emergent adverse events (TEAEs)

    The number of participants experiencing any TEAEs, serious TEAEs, discontinuation due to TEAEs and death will be reported

    Time frame: from study baseline (day 1) up to maximum 88 months

Secondary outcomes

  1. Annualized bleeding rate (ABR)

    Annualized bleeding rate (ABR) in the treatment period

    Time frame: from first ever dose of fitusiran (day 1) up to maximum 78 months

  2. Annualized spontaneous bleeding rate

    Annualized spontaneous bleeding rate in the treatment period

    Time frame: from first ever dose of fitusiran (day 1) up to maximum 78 months

  3. Annualized joint bleeding rate

    Annualized joint bleeding rate in the treatment period

    Time frame: from first ever dose of fitusiran (day 1) up to maximum 78 months

  4. Changes in Haem-A-quality of life (QoL) score

    Change in Haem A QoL physical health score and total score in the treatment period (in participants ≥17 years of age) from first ever dose of fitusiran (day 1) up to maximum 78 months

    Time frame: from first ever dose of fitusiran (day 1) up to maximum 78 months

07

Study locations

79 sites
  • Phoenix Childrens Hospital Site Number : 8400009
    Phoenix, Arizona 85016, United States
  • Children's Hospital Los Angeles Site Number : 8400019
    Los Angeles, California 90027, United States
  • Center for Inherited Blood Disorders (CIBD) Site Number : 8400016
    Orange, California 92868, United States
  • Nemours Children's Clinic Site Number : 8400008
    Jacksonville, Florida 32207, United States
  • St Joseph's Children's Hospital of Tampa Site Number : 8400002
    Tampa, Florida 33607, United States
  • Rush University Medical Center -1725 W Harrison St Site Number : 8400001
    Chicago, Illinois 60612-3863, United States
  • ~Massachusetts General Hospital Site Number : 8400011
    Boston, Massachusetts 02114, United States
  • University of Michigan Hospital - 1500 E Medical Center Dr Site Number : 8400012
    Ann Arbor, Michigan 48109-5000, United States
  • Alliance for Childhood Diseases Site Number : 8400007
    Las Vegas, Nevada 89135-3011, United States
  • Childrens Hospital Medical Center of Akron Site Number : 8400006
    Akron, Ohio 44308, United States
  • Investigational Site Number : 0360001
    Camperdown, New South Wales 2050, Australia
  • Investigational Site Number : 0360003
    Prahran, Victoria 3181, Australia
  • Investigational Site Number : 0360002
    Murdoch, Western Australia 6961, Australia
  • Investigational Site Number : 1240001
    Montreal, Quebec H1T 2M4, Canada
  • Investigational Site Number : 1560004
    Beijing, 100045, China
  • Investigational Site Number : 1560007
    Beijing, 100730, China
  • Investigational Site Number : 1560014
    Changsha, 410008, China
  • Investigational Site Number : 1560009
    Chengdu, 610091, China
  • Investigational Site Number : 1560002
    Guangzhou, 510515, China
  • Investigational Site Number : 1560011
    Guiyang, 550004, China
  • Investigational Site Number : 1560005
    Hangzhou, 89147, China
  • Investigational Site Number : 1560008
    Jinan, 250013, China
  • Investigational Site Number : 1560012
    Kunming, 650000, China
  • Investigational Site Number : 1560013
    Lanzhou, 730000, China
  • Investigational Site Number : 1560010
    Qingdao, 266555, China
  • Investigational Site Number : 1560003
    Shanghai, 200025, China
  • Investigational Site Number : 1560006
    Suzhou, 215006, China
  • Investigational Site Number : 2080001
    Copenhagen, 2100, Denmark
  • Investigational Site Number : 2500002
    Lyon, 69677, France
  • Investigational Site Number : 2500003
    Paris, 75015, France
  • Investigational Site Number : 2760001
    Berlin, 10249, Germany
  • Investigational Site Number : 2760003
    Leipzig, 04103, Germany
  • Investigational Site Number : 3480002
    Budapest, 1134, Hungary
  • Investigational Site Number : 3560001
    Bangalore, 560034, India
  • Investigational Site Number : 3560005
    Lucknow, 226003, India
  • Investigational Site Number : 3560007
    Mumbai, 400 022, India
  • Investigational Site Number : 3560002
    Pune, 411001, India
  • Investigational Site Number : 3560010
    Pune, 411004, India
  • Investigational Site Number : 3560004
    Ranipet, 632517, India
  • Investigational Site Number : 3720001
    Crumlin, Dublin 12, Ireland
  • Investigational Site Number : 3720002
    Dublin, 8, Ireland
  • Investigational Site Number : 3760001
    Ramat Gan, 5262100, Israel
  • Investigational Site Number : 3800002
    Milan, Lombardy 20122, Italy
  • Investigational Site Number : 3800004
    Padua, Veneto 35128, Italy
  • Investigational Site Number : 3920002
    Nishinomiya, Hyōgo 663-8501, Japan
  • Investigational Site Number : 3920005
    Isehara, Kanagawa 2591193, Japan
  • Investigational Site Number : 3920003
    Kitakyushu, 8078555, Japan
  • Investigational Site Number : 3920001
    Nagoya, 4668560, Japan
  • Investigational Site Number : 3920004
    Saitama, 330-8777, Japan
  • Investigational Site Number : 3920008
    Tokyo, 1600023, Japan
  • Investigational Site Number : 4580003
    Ampang, 68000, Malaysia
  • Investigational Site Number : 4580001
    Johor Bahru, 80100, Malaysia
  • Investigational Site Number : 4580002
    Kota Kinabalu, 88586, Malaysia
  • Investigational Site Number : 7100002
    Port Elizabeth, 6001, South Africa
  • Investigational Site Number : 4100001
    Busan, Busan 602-739, South Korea
  • Investigational Site Number : 4100002
    Daejeon, Daejeon 35233, South Korea
  • Investigational Site Number : 4100003
    Seoul, Seoul-teukbyeolsi 03722, South Korea
  • Investigational Site Number : 4100004
    Seoul, 3722, South Korea
  • Investigational Site Number : 1580002
    Changhua, 500, Taiwan
  • Investigational Site Number : 1580008
    Taichung, 40201, Taiwan
  • Investigational Site Number : 1580004
    Taichung, 40705, Taiwan
  • Investigational Site Number : 1580003
    Taipei, 100, Taiwan
  • Investigational Site Number : 1580001
    Taipei, 110, Taiwan
  • Investigational Site Number : 1580005
    Taipei, 112, Taiwan
  • Investigational Site Number : 1580007
    Taoyuan City, 33305, Taiwan
  • Investigational Site Number : 7920002
    Adana, 01130, Turkey (Türkiye)
  • Investigational Site Number : 7920004
    Akdeniz, 07059, Turkey (Türkiye)
  • Investigational Site Number : 7920012
    Bornova, 35100, Turkey (Türkiye)
  • Investigational Site Number : 7920006
    Gaziantep, 27100, Turkey (Türkiye)
  • Investigational Site Number : 7920005
    Istanbul, 34093, Turkey (Türkiye)
  • Investigational Site Number : 7920003
    Izmir, TR-35100, Turkey (Türkiye)
  • Investigational Site Number : 7920008
    Kayseri, 38039, Turkey (Türkiye)
  • Investigational Site Number : 7920007
    Samsun, 55200, Turkey (Türkiye)
  • Investigational Site Number : 8040001
    Kyiv, 04060, Ukraine
  • Investigational Site Number : 8040003
    Kyiv, 1135, Ukraine
  • Investigational Site Number : 8040002
    Lviv, 79044, Ukraine
  • Investigational Site Number : 8040004
    Mykolaiv, 54058, Ukraine
  • Investigational Site Number : 8260001
    London, London, City of SE1 9RT, United Kingdom
  • Investigational Site Number : 8260004
    Glasgow, G4 0SF, United Kingdom
08

References and documents

Publications

  • Young G, Kavakli K, Klamroth R, Matsushita T, Peyvandi F, Pipe SW, Rangarajan S, Shen MC, Srivastava A, Sun J, Tran H, You CW, Zulfikar B, Menapace LA, Zhang C, Shen Y, Puurunen M, Demissie M, Kenet G. Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study. Blood. 2025 Jun 19;145(25):2966-2977. doi: 10.1182/blood.2024027008. PubMed 40053895 ↗

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in Sep 2026, 92 months.

Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's 92 months is above that.

Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Nov 2026 → Sep 2026 and completion Nov 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2018
First posted
Nov 27, 2018
StartActual
Jan 9, 2019
Primary completionActual
Sep 14, 2026was Nov 2026
CompletionActual
Sep 14, 2026was Nov 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Sep 30, 2026
Primary completion
Nov 5, 2026→Sep 14, 2026 (actual)
Sep 30, 2026
Study completion
Nov 5, 2026→Sep 14, 2026 (actual)
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Active, not recruiting→Completed
    Primary completion Nov 5, 2026→Sep 14, 2026 (now actual)
    Study completion Nov 5, 2026→Sep 14, 2026 (now actual)
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03754790
Responsible party
Sponsor
First posted
Nov 27, 2018
Start date
Jan 9, 2019
Primary completion
Sep 14, 2026
Completion
Sep 14, 2026
Last update
Sep 30, 2026

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fitusiran

Start the discussion